# PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide

Source: https://onco.cc/trials/nct02814968/  
OnCo record `nct02814968` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Whole-body MRI in Prostate cancer, run by The European Uro-Oncology Group, completed.

## Summary

PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide is a phase 2 interventional study registered as NCT02814968 by The European Uro-Oncology Group, with 66 participants recorded, started 2015-02 and reaching its primary completion in 2020-06. Interventions recorded: Enzalutamide, 18-FDG PET/CT, Whole body MRI, Bone scan. Conditions recorded: Prostate Cancer Metastatic.

Linked to the technology Whole-body MRI because the registry names it ("whole body mri") among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02814968
- Phase: 2
- Setting: A Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide in Chemo-Naïve Patients With Progressive Prostate Cancer Who Have Failed Androgen Deprivation Therapy (Castration-resistant Prostate Cancer Patients)
- Sponsor: The European Uro-Oncology Group
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT02814968: https://clinicaltrials.gov/study/NCT02814968

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Whole-body MRI](https://onco.cc/technologies/whole-body-mri/)
- drugs: [Enzalutamide](https://onco.cc/drugs/enzalutamide/)

---
JSON: https://onco.cc/api/v1/entities/nct02814968.json